Cytokinetics Highlights Will Present Added Results From COSMIC-HF Phase 2 Trial At American Heart Association Scientific Sessions 2019

Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv

Benzinga · 11/11/2019 14:06

Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv mecarbil in patients with chronic heart failure, will be presented in an Abstract Rapid Fire Oral presentation at the American Heart Association Scientific Sessions 2019 in Philadelphia on November 18, 2019. 

Title: The Effect of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Diastolic Filling and Function in Chronic Systolic Heart Failure (COSMIC-HF)
Poster Presenter: Tor Biering-Sørensen, M.D., Herlev & Gentofte Hospital and Associate Professor, University of Copenhagen
Date: November 18, 2019
Session: Pharmacological Therapy in HF/Cardiomyopathy: The Next Important Indication or Agent?
Session Number: HF.RFO37
Time: 2:45 – 2:50 PM
Poster Number: RF299
Location: Zone 4, Science and Technology Hall